ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
ADC Therapeutics SA (ADCT) reported a Q3 loss of $0.42 per share, missing the Zacks Consensus Estimate of a $0.36 loss. This is an improvement from the $0.58 loss per share a year ago.
November 07, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ADC Therapeutics reported a Q3 loss of $0.42 per share, which is worse than the expected $0.36 loss. However, it shows improvement from the previous year's $0.58 loss.
The reported loss per share of $0.42 is worse than the expected $0.36, which is likely to negatively impact the stock price in the short term. However, the improvement from last year's $0.58 loss may provide some positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100